Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Eton Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $63.65, Eton Pharmaceuticals, Inc. trades at 35.7x trailing earnings, 12.9x sales and 20.8x book value, with an EV/EBITDA of 40.4. Over the last twelve months it generated about $143M of revenue and $51M of net income. It runs a gross margin of 69.2%, an operating margin of 28.8% and a net margin of 35.3%. It shows return on equity of 104.8%, return on invested capital of 35.4% and a free cash flow yield of 2.1%. On the balance sheet: a debt-to-equity ratio of 0.28 and a current ratio of 1.79. Over the past 52 weeks the share price ranged from $14.27 to $70.64, with a beta of 0.83.
Eton Pharmaceuticals, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.